Study details
Enrolling now
Pioglitazone Trial for Kidney Disease
The University of Texas at Arlington
NCT IDNCT03471117ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
28
Study length
about 8 years
Ages
35–70
Locations
2 sites in TX
What this study is about
This trial is testing whether a short-term treatment with pioglitazone can reduce sympathetic nerve activity in people with chronic kidney disease. The goal is to see if pioglitazone helps lower the risk of cardiovascular problems and death in these patients.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take Pioglitazone
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
pioglitazone (Thiazolidinedione; improves insulin sensitivity by activating PPAR-gamma)
Drug routes
oral (Oral Tablet)
Body systems
Renal